8-K: SeaStar Medical Granted Nasdaq Extension to Regain Compliance

SeaStar Medical has received a temporary extension from Nasdaq until June 24, 2024, to regain compliance with the minimum bid price rule.

Summary

• SeaStar Medical received a letter from Nasdaq granting a temporary exception to regain compliance with the minimum bid price rule.
• The company's stock price has been below $1.00 for 30 consecutive business days prior to June 26, 2023, which triggered the non-compliance notice.
• The extension requires the company to maintain a closing bid price of $1.00 or more per share for a minimum of ten consecutive trading sessions by June 24, 2024.
• SeaStar Medical had previously submitted a plan to Nasdaq that included a potential reverse stock split by June 7, 2024, if necessary.
• The company will monitor its stock price and consider all available options to regain compliance.

Sentiment

Score: 3

Explanation: The sentiment is negative due to the company's non-compliance with Nasdaq listing rules and the uncertainty surrounding its ability to regain compliance. The extension provides some relief, but the underlying issue of a low stock price remains a concern.

Positives

• The extension provides SeaStar Medical with additional time to regain compliance with Nasdaq listing requirements.
• The company has a plan in place, including a potential reverse stock split, to address the non-compliance issue.

Negatives

• SeaStar Medical's stock has been trading below the required $1.00 minimum bid price for an extended period.
• There is no guarantee that the company will be able to regain compliance with the minimum bid price rule.

Risks

• There is a risk that SeaStar Medical may not be able to maintain a $1.00 or higher share price for ten consecutive trading sessions by June 24, 2024.
• The company may need to implement a reverse stock split, which could negatively impact shareholders.
• Failure to regain compliance could result in delisting from the Nasdaq Capital Market.

Future Outlook

The company intends to monitor its stock price and consider all available options to regain compliance with the minimum bid price rule by June 24, 2024. There is no assurance that the company will be able to regain compliance.

Management Comments

• The company intends to monitor the closing bid price of its Common Stock and consider available options if its Common Stock does not trade at a level likely to result in the Company's regaining compliance with the Minimum Bid Price Rule by June 24, 2024.

Industry Context

This announcement is specific to SeaStar Medical's compliance with Nasdaq listing requirements and does not directly relate to broader industry trends. However, it highlights the challenges faced by companies with low stock prices in maintaining their listing status.

Comparison to Industry Standards

• Many companies listed on the Nasdaq Capital Market face similar challenges in maintaining the minimum bid price requirement.
• Reverse stock splits are a common strategy used by companies to regain compliance with listing rules.
• The specific circumstances of SeaStar Medical are unique to its financial performance and stock price history.

Stakeholder Impact

• Shareholders face the risk of further stock price decline if the company fails to regain compliance.
• Employees may be concerned about the company's long-term viability.
• Creditors may be more cautious about extending credit to the company.

Next Steps

• SeaStar Medical will monitor its stock price.
• The company will consider available options to regain compliance.
• A reverse stock split may be implemented by June 7, 2024.

Key Dates

Keywords

Nasdaq, Minimum Bid Price Rule, Compliance, Reverse Stock Split, Delisting, Stock Price